Anti-Mouse CD70 Antibody (FR70)
Based on 1 Customer Validation
Anti-Mouse CD70 Antibody (FR70) is a rat-derived ant-mouse CD70 IgG2b κ type antibody inhibitor. Anti-Mouse CD70 Antibody (FR70) decreases CD4+, CD8+ T cells and eosinophils. Anti-Mouse CD70 Antibody (FR70) shows potent anti-inflammatory and anti-immune effects on allergic lung inflammation and cardiac transplant mice models.
For research use only. We do not sell to patients.
- Purity: 95.00%
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Rat IgG2b kappa
Mouse
CD70
The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Anti-Mouse CD70 Antibody (FR70) (500 μg on the day of transplantation and 250 μg/dose on days 1, 3, and 5 posttransplantation, i.p.) causes long-term mouse cardiac allograft acceptance with induction of tolerogenic dendritic cells[2].
Anti-Mouse CD70 Antibody (FR70) (300 μg, i.p., at days 0, 2, 4, 7, 11, 14, 16, 18, 22, 25, and 28) shows a potent inhibition of the inflammatory response in a murine model of allergic lung inflammation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (H-2b) mice transplanted with fully major histocompatibility complexmismatched BALB/c (H-2d) vascularized cardiac grafts (6-8weeks)[1]
-
Dosage:500 μg on the day of transplantation and 250 μg/dose on days 2, 4, and 6 posttransplantation
-
Administration:Intraperitoneally injection for 4 times
-
Result:Significant prolonged graft survival.
Reduced the infiltration of CD8+ and CD4+ T cells into the graft at day 8.
Showed low levels of CD8+ and CD4+ T cells in grafts harvested at day 15.
Resulted in lower levels of donor-specific IgG in the sera derived from peripheral blood.
Decreased percentage of splenic CD4+CD25+Foxp3+ cells.
-
Animal Model:C3H recipient mice with B6 heterotopic cardiac transplantation (8-12 weeks)[2]
-
Dosage:500 μg on the day of transplantation and 250 μg/dose on days 1, 3, and 5 posttransplantation
-
Administration:Intraperitoneally injection for 4 times
-
Result:Induced long term cardiac allograft acceptance, with an MST of about 100 days.
Had a significantly smaller population of cytotoxic CD8+ T cells in graft-infiltrating lymphocytes and Spleen at day 7.
Decreased the expression of perforin and IFN-γ in the spleen.
Downregulated the expression of CD40, CD80, CD86, IL-6, IL-12β and MHC class II proteins and upregulated the levels of PD-L1, heme oxygenase-1 (HO-1) and indoleamine 2,3-dioxygenase (IDO1).
Generated regulatory cells (Tregs).
Increased the population of CD25+ Foxp3+ cells and levels of Foxp3 mRNA and IL-10 among the CD4+ graft-infiltrating lymphocytes.
-
Animal Model:Allergic lung inflammation mice models induced by ovalbumin (BALB/cByJJcl, female, 6-8 weeks) [3]
-
Dosage:300μg
-
Administration:Intraperitoneally injection, at days 0, 2, 4, 7, 11, 14, 16, 18, 22, 25, and 28
-
Result:Significantly reduced the accumulation of eosinophils and lymphocytesand production of Th2 cytokines (IL-4 and IL-13) in BAL fluid and eosinophilia and mucus overproduction in the lung.
Reduced the ovalbumin-specific proliferative response and the levels of IL-4, IL-5, and IL-13.
Significantly inhibited the development of airway hyperreactivity, the accumulation of eosinophils in the lung, and the ovalbumin-specific proliferative response and production of Th2 cytokines (IL-5 and IL-13) in LN cells.
Inhibited the development of CD272 Th2 Cells.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
in vivo CD70 blockade; in vitro CD70 blockade; Flow cytometry
Chemical Information
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD70 Antibody (FR70)]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (266 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Shariff H, et al. Role of the Fc region in CD70-specific antibody effects on cardiac transplant survival. Transplantation. 2011 Dec 15;92(11):1194-201. [Content Brief]
[2]. Zhao J, et al. Monotherapy With Anti-CD70 Antibody Causes Long-Term Mouse Cardiac Allograft Acceptance With Induction of Tolerogenic Dendritic Cells. Front Immunol. 2021 Feb 19;11:555996. [Content Brief]
[3]. Makino F, et al. Blockade of CD70-CD27 interaction inhibits induction of allergic lung inflammation in mice. Am J Respir Cell Mol Biol. 2012 Sep;47(3):298-305. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD70 Antibody (FR70) Related Classifications
HY-P990264 Related Classifications
Powered by Bioz